Schizophrenia and increased risks of cardiovascular disease

被引:841
作者
Hennekens, CH
Hennekens, AR
Hollar, D
Casey, DE
机构
[1] Florida Atlantic Univ, Ctr Excellence Biomed & Marine Biotechnol, Dept Biomed Sci, Boca Raton, FL 33431 USA
[2] Univ Miami, Sch Med, Dept Med, Coral Gables, FL 33124 USA
[3] Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Coral Gables, FL 33124 USA
[4] Boston Univ, Sch Social Work, Boston, MA 02215 USA
[5] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA
[6] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA
关键词
D O I
10.1016/j.ahj.2005.02.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The aim of the study is to review the absolute and relative impacts of the major causes for premature mortality among patients with schizophrenia. Data sources We reviewed published articles on causes of mortality in the general population as well as among patients with schizophrenia. Study selection We selected articles which published total and cause-specific mortality rates. Data extraction We reviewed the causes of mortality and their risk factors. Data synthesis The average life expectancy of the general population is 76 years (72 years in men, 80 years in women), whereas the corresponding figure is 61 years (57 years in men, 65 years in women) among patients with schizophrenia. Thus, patients with schizophrenia have approximately a 20% reduced life expectancy compared with the general population. Although patients with schizophrenia are 10 to 20 times more likely than,the general population to commit suicide, more than two thirds of patients with schizophrenia, compared with approximately one-half in the general population, die of coronary heart disease (CHD). The chief risk factors for this excess risk of death are cigarette smoking, obesity leading to dyslipidemia, insulin resistance and diabetes, and hypertension. Conclusions The chief cause of excess premature mortality among patients with schizophrenia is CHID, caused mainly by their adverse risk factor profile. Because patients with schizophrenia have less access to medical care, consume less medical care, and are less compliant with their regimens, the choice of antipsychotic drug regimens that do not further adversely affect their risk factor for CHD is a major clinical and public health challenge among patients with schizophrenia.
引用
收藏
页码:1115 / 1121
页数:7
相关论文
共 58 条
[1]   The distribution of body mass index among individuals with and without schizophrenia [J].
Allison, DB ;
Fontaine, KR ;
Heo, M ;
Mentore, JL ;
Cappelleri, JC ;
Chandler, LP ;
Weiden, PJ ;
Cheskin, LJ .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (04) :215-220
[2]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[3]  
Arauz-Pacheco Carlos, 2004, Diabetes Care, V27 Suppl 1, pS65
[4]  
Bonanno DG, 2001, ANN PHARMACOTHER, V35, P563
[5]   Causes of the excess mortality of schizophrenia [J].
Brown, S ;
Inskip, H ;
Barraclough, B .
BRITISH JOURNAL OF PSYCHIATRY, 2000, 177 :212-217
[6]  
Brugman N J, 2000, Ned Tijdschr Geneeskd, V144, P437
[7]  
Casey DE, 2004, J CLIN PSYCHIAT, V65, P4
[8]  
CASEY DE, 2003, MED ILLNESS SCHIZOPH, P13
[9]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[10]   BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].
COLLINS, R ;
PETO, R ;
MACMAHON, S ;
HEBERT, P ;
FIEBACH, NH ;
EBERLEIN, KA ;
GODWIN, J ;
QIZILBASH, N ;
TAYLOR, JO ;
HENNEKENS, CH .
LANCET, 1990, 335 (8693) :827-838